• Molecular NameMarinol
  • SynonymNA
  • Weight314.469
  • Drugbank_IDDB00470
  • ACS_NO1972-08-3
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)7.08
  • pka10.6
  • LogD (pH=7, predicted)7.07
  • Solubility (experiment)2.8 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-5.79
  • LogSw (predicted, AB/LogsW2.0)0.0
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors1
  • No.of HBond Acceptors2
  • No.of Rotatable Bonds4
  • TPSA29.46
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyThe main psychoactive substance found in the cannabis plant.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability10.0
  • Protein binding97.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmMostly hepatic by CYP2C
  • Half life1.6~59 h, 25~36 h (orally administered Dronabinol)
  • Excretion65-80% (feces), 20-35% (urine) as acid metabolites
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThe most frequently reported adverse experiences in patients with AIDS during placebo-controlled clinical trials involved the CNS and were reported by 33% of patients receiving MARINOL Capsules. About 25% of patients reported a minor CNS adverse event during the first 2 weeks and about 4% reported such an event each week for the next 6 weeks thereafter.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A